Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.
Cancers (Basel). 2021 Jun 30;13(13):3296. doi: 10.3390/cancers13133296.
Cancers (Basel). 2021.
PMID: 34209457
Free PMC article.
Review.
Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012.
Bonadies N, Feller A, Rovo A, Ruefer A, Blum S, Gerber B, Stuessi G, Benz R, Cantoni N, Holbro A, Schmidt A, Lehmann T, Wilk CM, Arndt V; NICER Working Group.
Bonadies N, et al. Among authors: stuessi g.
Cancer Epidemiol. 2017 Feb;46:85-92. doi: 10.1016/j.canep.2016.12.005. Epub 2017 Jan 2.
Cancer Epidemiol. 2017.
PMID: 28056392
Item in Clipboard
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).
Ossenkoppele GJ, et al. Among authors: stuessi g.
Leukemia. 2020 Jul;34(7):1751-1759. doi: 10.1038/s41375-020-0725-0. Epub 2020 Feb 4.
Leukemia. 2020.
PMID: 32020044
Clinical Trial.
Item in Clipboard
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).
Ossenkoppele GJ, et al. Among authors: stuessi g.
Leukemia. 2020 Oct;34(10):2820. doi: 10.1038/s41375-020-0994-7.
Leukemia. 2020.
PMID: 32733013
Item in Clipboard
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK).
Löwenberg B, et al.
Blood. 2010 Apr 1;115(13):2586-91. doi: 10.1182/blood-2009-10-246470. Epub 2010 Jan 26.
Blood. 2010.
PMID: 20103782
Free article.
Clinical Trial.
Item in Clipboard
Item in Clipboard
Cite
Cite